VCEL Vericel Corporation

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2024.

Second Quarter 2024 Financial Highlights

• Total net revenue of $52.7 million
• MACI® net revenue growth of 21% to $44.1 million
• Burn Care net revenue of $8.5 million, consisting of $7.8 million of Epicel® revenue and $0.8 million of NexoBrid® revenue
• Gross margin of 70%, an increase of 430 basis points versus the prior year
• Net loss of $4.7 million, or $0.10 per diluted share
• Non-GAAP adjusted EBITDA increased 42% to $6.3 million, representing adjusted EBITDA margin of 12%, an increase of approximately 230 basis points versus the prior year
• Operating cash flow of approximately $18.5 million
• As of June 30, 2024, the Company had approximately $154 million in cash, restricted cash and investments, and no debt

First Half 2024 Financial Highlights

• Total net revenue increased 20% to $103.9 million
• MACI net revenue growth of 20% to $84.3 million
• Burn Care net revenue growth of 20% to $19.6 million
• Gross margin of 69%, an increase of approximately 430 basis points versus the prior year
• Net loss of $8.5 million, or $0.18 per diluted share
• Non-GAAP adjusted EBITDA increased 120% to $13.5 million, representing adjusted EBITDA margin of 13%, an increase of approximately 600 basis points versus the prior year
• Operating cash flow of approximately $26 million

Business Highlights and Updates

• Record second quarter total revenue and MACI revenue
• Second highest number of MACI biopsies and surgeons taking biopsies in a quarter since launch, including the highest number of biopsies in any month since launch
• Commercial plans progressing for MACI Arthro™ in advance of anticipated launch later this quarter
• NexoBrid launch progressing with approximately 70 Pharmacy and Therapeutics (P&T) committee submissions, more than 40 burn centers obtaining approval and approximately 40 centers placing initial orders
• FDA approval of pediatric indication for NexoBrid expected in the third quarter of 2024

“The Company had another strong quarter as we generated record second quarter revenue, highlighted by continued high growth for MACI and solid progression in NexoBrid demand, and delivered another quarter of significant margin expansion as our growth in profitability continues to outpace our high revenue growth,” said Nick Colangelo, President and CEO of Vericel. “In light of the strong performance of our core portfolio in the first half of the year, with both MACI and the Burn Care franchise delivering 20% growth, and with the expected contributions from new product launches, we believe that the Company is very well-positioned for continued high revenue and profit growth in 2024 and beyond.”

2024 Financial Guidance

• Reaffirmed total net revenue guidance of $238 to $242 million, or 20% to 23% growth
• Profitability guidance raised to 71% gross margin and 21% adjusted EBITDA margin, compared to the previous guidance of 70% and 20%, respectively

Second Quarter 2024 ResultsTotal net revenue for the quarter ended June 30, 2024 increased 15% to $52.7 million, compared to $45.9 million in the second quarter of 2023. Total net product revenue for the quarter included $44.1 million of MACI (autologous cultured chondrocytes on porcine collagen membrane) net revenue, $7.8 million of Epicel (cultured epidermal autografts) net revenue, and $0.8 million of NexoBrid (anacaulase-bcdb) net revenue, compared to $36.3 million of MACI net revenue and $9.6 million of Epicel net revenue, respectively, in the second quarter of 2023.

Gross profit for the quarter ended June 30, 2024 was $36.6 million, or 70% of net revenue, compared to $29.9 million, or 65% of net revenue, for the second quarter of 2023.

Total operating expenses for the quarter ended June 30, 2024 were $42.6 million, compared to $35.9 million for the same period in 2023. The increase in operating expenses was primarily due to development and pre-launch activities for MACI Arthro, increased headcount and related employee expenses, and lease expense associated with the Company’s new facility that is under construction.

Net loss for the quarter ended June 30, 2024 was $4.7 million, or $0.10 per diluted share, compared to $5.0 million, or $0.11 per diluted share, for the second quarter of 2023.

Non-GAAP adjusted EBITDA for the quarter ended June 30, 2024 was $6.3 million, or 12% of net revenue, compared to $4.4 million, or 10% of net revenue, for the second quarter of 2023. A table reconciling non-GAAP measures is included in this press release for reference.

As of June 30, 2024, the Company had approximately $154 million in cash, restricted cash and investments, and no debt.

Conference Call Information Today’s conference call will be available live at 8:30 a.m. Eastern Time and can be accessed through the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. A slide presentation with highlights from today’s conference call will be available on the webcast and in the Investor Relations section of the Vericel website. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software, if necessary. To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until August 1, 2025.

About Vericel CorporationVericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

GAAP v. Non-GAAP MeasuresVericel’s reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. Vericel has provided in this release certain financial information that has not been prepared in accordance with GAAP. Vericel’s management believes that the non-GAAP adjusted EBITDA described in this release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Vericel’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Vericel’s industry. However, the non-GAAP financial measures that Vericel uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Forward-Looking StatementsVericel cautions you that all statements other than statements of historical fact included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Our actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.

Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI, Epicel, and NexoBrid, growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, including the timely completion of a new headquarters and manufacturing facility in Burlington, Massachusetts, the ability to achieve or sustain profitability, contributions to adjusted EBITDA, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA’s potential approval of the arthroscopic delivery of MACI to the knee or the use of MACI to treat cartilage defects in the ankle, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, physician and burn center adoption of NexoBrid, supply chain disruptions or other events or factors affecting MediWound’s ability to manufacture and supply sufficient quantities of NexoBrid to meet customer demand, including but not limited to the ongoing Israel-Hamas war or other military conflicts in the Middle East, negative impacts on the global economy and capital markets resulting from the conflict in Ukraine and the Israel-Hamas war, adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, global geopolitical tensions or record inflation and potential future impacts on our business or the economy generally stemming from a resurgence of COVID-19 or another similar public health emergency.

These and other significant factors are discussed in greater detail in Vericel’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on February 29, 2024, Vericel’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 1, 2024, and in other filings with the SEC. These forward-looking statements reflect our views as of the date hereof and Vericel does not assume and specifically disclaims any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

Investor Contact:Eric Burnsir@vcel.com+1 (734) 418-4411

Media Contact:Julie Downsmedia@vcel.com

VERICEL CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts - unaudited)
	Three Months Ended June 30,								Six months ended June 30,
		2024				2023				2024				2023
Product sales, net	$	52,662			$	45,922			$	103,943			$	86,939
Total revenue		52,662				45,922				103,943				86,939
Cost of product sales		16,061				15,981				31,988				30,478
Gross profit		36,601				29,941				71,955				56,461
Research and development		7,363				5,253				13,781				10,465
Selling, general and administrative		35,269				30,649				69,669				60,134
Total operating expenses		42,632				35,902				83,450				70,599
Loss from operations		(6,031	)			(5,961	)			(11,495	)			(14,138	)
Other income (expense):
Interest income		1,510				1,095				3,272				1,934
Interest expense		(153	)			(149	)			(306	)			(294	)
Other expense		(8	)			(5	)			(15	)			(17	)
Total other income		1,349				941				2,951				1,623
Net loss	$	(4,682	)		$	(5,020	)		$	(8,544	)		$	(12,515	)
Net loss per common share:
Basic and diluted	$	(0.10	)		$	(0.11	)		$	(0.18	)		$	(0.26	)
Weighted-average common shares outstanding:
Basic and diluted		48,686				47,572				48,413				47,480

VERICEL CORPORATIONRECONCILIATION OF REPORTED NET LOSS (GAAP) TO ADJUSTED EBITDA (NON-GAAP MEASURE)(in thousands - unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
			2024				2023				2024				2023
Net loss		$	(4,682	)		$	(5,020	)		$	(8,544	)		$	(12,515	)
Stock-based compensation expense			9,520				8,761				19,354				17,492
Depreciation and amortization			1,323				1,171				2,701				2,329
Net interest income			(1,357	)			(946	)			(2,966	)			(1,640	)
Pre-occupancy lease expense			1,509				475				2,986				475
Adjusted EBITDA (Non-GAAP)		$	6,313			$	4,441			$	13,531			$	6,141

VERICEL CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands - unaudited)
	June 30,				December 31,
		2024				2023
ASSETS
Current assets:
Cash and cash equivalents	$	50,291			$	69,088
Restricted cash		25,563				17,778
Short-term investments		52,217				40,469
Accounts receivable (net of allowance for doubtful accounts of $10 and $43, respectively)		47,996				58,356
Inventory		14,887				13,087
Other current assets		6,432				6,853
Total current assets		197,386				205,631
Property and equipment, net		73,086				41,635
Intangible assets, net		6,563				6,875
Right-of-use assets		73,020				73,462
Long-term investments		26,120				25,283
Other long-term assets		664				771
Total assets	$	376,839			$	353,657
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	25,216			$	22,347
Accrued expenses		12,856				17,215
Current portion of operating lease liabilities		5,791				6,187
Total current liabilities		43,863				45,749
Operating lease liabilities		89,801				81,856
Other long-term liabilities		198				100
Total liabilities	$	133,862			$	127,705
Total shareholders’ equity		242,977				225,952
Total liabilities and shareholders’ equity	$	376,839			$	353,657